Submitted by Anonymous (not verified) on 22 September 2023 - 16:40
Human medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Lymphoma, Mantle-Cell;Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 21/10/2014, Revision: 31, Status: Authorised
Source: